# Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer

> **NCT01218880** · PHASE1 · UNKNOWN · sponsor: **Protgen Ltd** · enrollment: 21 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** M2ES 7.5mg
- **DRUG:** M2ES 15mg
- **DRUG:** M2ES 30mg
- **DRUG:** M2ES 45mg

## Key facts

- **NCT ID:** NCT01218880
- **Lead sponsor:** Protgen Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-12
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2010-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218880, "Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01218880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*